Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2016 3
2017 3
2019 1
2020 1
2022 1
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases.
Płotka A, Przybyłowicz-Chalecka A, Korolczuk M, Kanduła Z, Ratajczak B, Kiernicka-Parulska J, Mierzwa A, Godziewska K, Jarmuż-Szymczak M, Gil L, Lewandowski K. Płotka A, et al. Among authors: przybylowicz chalecka a. Mol Cytogenet. 2023 Jul 3;16(1):14. doi: 10.1186/s13039-023-00645-1. Mol Cytogenet. 2023. PMID: 37400842 Free PMC article.
Clinical outcomes of therapy-related acute myeloid leukemia: an over 20-year single-center retrospective analysis.
Adamska M, Kowal-Wiśniewska E, Przybyłowicz-Chalecka A, Barańska M, Łojko-Dankowska A, Joks M, Kanduła Z, Jarmuż-Szymczak M, Gil L. Adamska M, et al. Among authors: przybylowicz chalecka a. Pol Arch Intern Med. 2023 Jan 24;133(1):16344. doi: 10.20452/pamw.16344. Epub 2022 Sep 27. Pol Arch Intern Med. 2023. PMID: 36165652 Free article.
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
Thompson RM, Dytfeld D, Reyes L, Robinson RM, Smith B, Manevich Y, Jakubowiak A, Komarnicki M, Przybylowicz-Chalecka A, Szczepaniak T, Mitra AK, Van Ness BG, Luczak M, Dolloff NG. Thompson RM, et al. Among authors: przybylowicz chalecka a. Oncotarget. 2017 May 30;8(22):35863-35876. doi: 10.18632/oncotarget.16262. Oncotarget. 2017. PMID: 28415782 Free PMC article.
The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure.
Ratajczak B, Przybyłowicz-Chalecka A, Czerwińska-Rybak J, Kanduła Z, Ustaszewski A, Gil L, Lewandowski K, Jarmuż-Szymczak M. Ratajczak B, et al. Among authors: przybylowicz chalecka a. Leuk Res. 2023 Sep;132:107349. doi: 10.1016/j.leukres.2023.107349. Epub 2023 Jun 28. Leuk Res. 2023. PMID: 37393627 Free article.
Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma.
Kubicki T, Dytfeld D, Barnidge DR, Sakrikar D, Przybyłowicz-Chalecka A, Jamroziak K, Robak P, Czyz J, Tyczynska A, Druzd-Sitek AA, Giannopoulos K, Wróbel T, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil LA, Puła B, Szukalski L, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T Prof, Jiang K, Cooperrider JH, Jakubowiak AJ, Derman BA. Kubicki T, et al. Among authors: przybylowicz chalecka a. Blood. 2024 May 7:blood.2024024041. doi: 10.1182/blood.2024024041. Online ahead of print. Blood. 2024. PMID: 38713888
Characterization and significance of the Philadelphia negative/BCR-ABL1 positive rearrangement or masked Philadelphia translocation in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single-center study.
Ratajczak B, Gniot M, Przybylowicz-Chalecka A, Czerwinska-Rybak J, Komarnicki M, Lewandowski K, Jarmuz-Szymczak M. Ratajczak B, et al. Among authors: przybylowicz chalecka a. Leuk Lymphoma. 2020 Jan;61(1):189-193. doi: 10.1080/10428194.2019.1648807. Epub 2019 Aug 7. Leuk Lymphoma. 2020. PMID: 31389273 No abstract available.
Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype - retrospective analysis of Polish Adult Leukemia Group (PALG).
Wierzbowska A, Wawrzyniak E, Siemieniuk-Rys M, Kotkowska A, Pluta A, Golos A, Robak T, Szarawarska M, Jaskowiec A, Duszenko E, Rybka J, Holojda J, Grosicki S, Pienkowska-Grela B, Woroniecka R, Ejduk A, Watek M, Wach M, Mucha B, Skonieczka K, Czyzewska M, Jachalska A, Klonowska A, Iliszko M, Knopinska-Posluszny W, Jarmuz-Szymczak M, Przybylowicz-Chalecka A, Gil L, Kopacz A, Holowiecki J, Haus O. Wierzbowska A, et al. Among authors: przybylowicz chalecka a. Leuk Lymphoma. 2017 Apr;58(4):889-897. doi: 10.1080/10428194.2016.1219901. Epub 2016 Aug 26. Leuk Lymphoma. 2017. PMID: 27561449
Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.
Dytfeld D, Luczak M, Wrobel T, Usnarska-Zubkiewicz L, Brzezniakiewicz K, Jamroziak K, Giannopoulos K, Przybylowicz-Chalecka A, Ratajczak B, Czerwinska-Rybak J, Nowicki A, Joks M, Czechowska E, Zawartko M, Szczepaniak T, Grzasko N, Morawska M, Bochenek M, Kubicki T, Morawska M, Tusznio K, Jakubowiak A, Komarnicki MA. Dytfeld D, et al. Among authors: przybylowicz chalecka a. Oncotarget. 2016 Aug 30;7(35):56726-56736. doi: 10.18632/oncotarget.11059. Oncotarget. 2016. PMID: 27527861 Free PMC article.
12 results